ClinicalTrials.Veeva

Menu

NeuralNET Cerebral Palsy Pilot Study

U

University of Cambridge

Status

Active, not recruiting

Conditions

Cerebral Palsy

Treatments

Genetic: Whole-genome sequencing

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05858268
IRAS: 319781

Details and patient eligibility

About

The NeuralNET Cerebral Palsy Pilot Study is testing a genetic testing pathway in the NHS for children with cerebral palsy (CP). Other studies suggest that almost one in three peoples' CP is caused by a change in their genes, but more studies are needed to confirm this. A genetic test called whole genome sequencing (WGS) will be used for children who have CP to look for rare changes in genes that cause the condition, and the results of the test will be given to children's doctors within 12 weeks. Knowing that CP has a genetic cause could lead to changes being made to a child's care or treatment that could improve their condition.

The study will test 66 children with CP from 3 hospitals, and also their biological parent(s), if they're available. Following informed consent, the investigators will collect a blood sample from everyone taking part which will be sent for WGS. It is important to understand what families think and feel about the testing. The investigators will ask parents/guardians of the children taking part to fill in two questionnaires, one before and one after WGS. Some parents/guardians will also be interviewed after getting the WGS result, to ask about their experience of the testing. The study will take up to 16 months per family.

The results of this pilot study will tell the investigators if it is feasible for the NHS to use WGS to test children with CP. If so, a larger study testing more children with CP can then be carried out to help decide if this type of WGS-based testing should be made available through the NHS to children with CP whose clinical care might be changed by the result. The genetic findings from this study will also be made available to other researchers and doctors to do more research into CP that might help improve general understanding of the condition and its potential treatment.

Enrollment

66 estimated patients

Sex

All

Ages

Under 15 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Children with cerebral palsy (CP):

  1. Has a clinical diagnosis of CP in the medical record
  2. Any GMFCS score (GMFCS 1-5)
  3. Does not have a known genetic diagnosis that explains the CP phenotype
  4. Has a parent/legal guardian available who can consent and is willing to complete study questionnaires
  5. Invited to participate by a clinician at a participating recruitment site

Biological parents of children with CP will also be included in the study if they are:

  1. A biological parent of the child
  2. Aged 18 years or above
  3. Willing and able to give informed consent for participation in the study Participant type

Exclusion criteria

Children with cerebral palsy (CP):

  1. Children that have a pre-existing genetic diagnosis from whole genome sequencing or whole-exome sequencing
  2. Children not matching the inclusion criteria

Biological parents of children with CP will be excluded from the study if they do not meet the biological parent inclusion criteria i.e. they ARE NOT:

  1. A biological parent of the child
  2. Aged 18 years or above
  3. Willing and able to give informed consent for participation in the study

Trial contacts and locations

1

Loading...

Central trial contact

Heather Pierce, PhD; Emily Li, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems